50
Participants
Start Date
June 4, 2018
Primary Completion Date
September 30, 2025
Study Completion Date
December 31, 2025
Seclidemstat
Twice daily administration of seclidemstat
Cyclophosphamide
250 mg/m2/day on Days 1 thru 5 of a 21-day cycle
Topotecan
0.75 mg/m2/day on Days 1 thru 5 of a 21-day cycle
Memorial Sloan Kettering Cancer Center, New York
Fox Chase Cancer Center, Philadelphia
Mayo Clinic, Jacksonville
H. Lee Moffitt Cancer Center and Research Institute, Tampa
Johns Hopkins All Children's Hospital, St. Petersburg
The Research Institute at Nationwide Children's Hospital, Columbus
Cleveland Clinic Taussig Cancer Institute, Cleveland
Mayo Clinic, Rochester
Washington University, St Louis
MD Anderson Cancer Center, Houston
Virginia Cancer Specialists, Fairfax
Children's Hospital Los Angeles, Los Angeles
Sarcoma Oncology Research Center, Santa Monica
Oregon Health Sciences University, Portland
University of Washington, Seattle
Dana-Farber Cancer Institute, Boston
National Pediatric Cancer Foundation
OTHER
Salarius Pharmaceuticals, LLC
INDUSTRY